Shannon N. Westin, MD, MPH

Risk factors and biomarker testing in conjunction with cancer staging may better identify ideal treatment for endometrial cancer than cancer staging alone.

Shannon N. Westin, MD, discusses chemotherapy options for endometrial cancer as well as the results of her phase 3 DUO-E trial.

Shannon N. Westin, MD, discusses how patient considerations for immunotherapy treatment involve evaluating individual health profiles, potential adverse effects, and the importance of personalized approaches to enhance treatment efficacy and patient quality of life.

Shannon N. Westin, MD, discusses how neoadjuvant treatment considerations for endometrial cancer can improve surgical outcomes and patient prognosis through the use of personalized, multidisciplinary approaches tailored to individual tumor characteristics.

Shannon N. Westin, MD, discusses the molecular classification of endometrial cancer.

Shannon N. Westin, MD, provides an overview of endometrial cancer to the Oncology Brothers.

Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.

Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.

CancerNetwork® sat down with Shannon N. Westin, MD, MPH, at the 2021 ASCO Annual Meeting to talk about the use of adavosertib in PARP inhibitor–resistant ovarian cancer.